Indacaterol

The First Once-daily Long-acting Beta2 Agonist for COPD

Inbunden, Engelska, 2013

1 419 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Here is a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled beta2 agonist for treating COPD. Covers design and pre-clinical pharmacology of the molecule, early clinical development, efficacy studies and more.

Produktinformation

Utgivningsdatum2013-11-27
Mått155 x 235 x 15 mm
Vikt407 g
FormatInbunden
SpråkEngelska
SerieMilestones in Drug Therapy
Antal sidor146
Upplaga2014
FörlagSpringer Basel
ISBN9783034807081

Tillhör följande kategorier

Lungmedicin inom Medicin
Farmakologi inom Medicin

Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?